Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.